Related Experiment Videos
Update on daptomycin: the first approved lipopeptide antibiotic.
Su Young Lee1, Hong Wei Fan, Joseph L Kuti
1Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, Connecticut 06102, USA.
Expert Opinion on Pharmacotherapy
|June 30, 2006
Summary
Daptomycin remains a potent antibiotic against resistant Gram-positive bacteria. This review focuses on updated susceptibility data, pharmacodynamics, and clinical use for infections like skin and bloodstream infections.
Area of Science:
- Infectious Diseases
- Pharmacology
- Microbiology
Background:
- Daptomycin is a lipopeptide antibiotic with broad Gram-positive activity.
- It is approved for complicated skin and skin structure infections.
- Previous reviews covered its basic properties and clinical use.
Purpose of the Study:
- To provide an updated summary of daptomycin's efficacy.
- Focus on recent global susceptibility data for key pathogens.
- Include new pharmacodynamic data and clinical evidence for specific infections.
Main Methods:
- Literature review of published studies.
- Analysis of global bacterial isolate susceptibility data.
- Synthesis of recent clinical trial and postmarketing surveillance data.
Main Results:
- Daptomycin maintains potent activity against resistant Gram-positive bacteria.
- Updated susceptibility data confirms efficacy against target pathogens.
- Recent clinical data supports its use in bacteraemia and endocarditis.
Conclusions:
- Daptomycin remains a critical therapeutic option for Gram-positive infections.
- Ongoing surveillance is essential to monitor resistance patterns.
- Further research into its application for complex infections is warranted.